

# Resource Summary Report

Generated by [SPARC SAWG](#) on Sep 13, 2026

## SRAMP

RRID:SCR\_024500

Type: Tool

### Proper Citation

SRAMP (RRID:SCR\_024500)

### Resource Information

**URL:** <http://www.cuilab.cn/sramp/>

**Proper Citation:** SRAMP (RRID:SCR\_024500)

**Description:** Software tool as computational predictor of mammalian m(6)A site. Used for prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features.

**Synonyms:** Sequence-based Rna Adenosine Methylation site Predictor

**Resource Type:** simulation software, software application, software resource

**Defining Citation:** [PMID:26896799](#)

**Keywords:** mammalian m(6)A site predictor, sequence derived features based predictor,

**Availability:** Free, Available for download, Freely available

**Resource Name:** SRAMP

**Resource ID:** SCR\_024500

**Record Creation Time:** 20231002T161336+0000

**Record Last Update:** 20260912T200048+0000

### Ratings and Alerts

No rating or validation information has been found for SRAMP.

No alerts have been found for SRAMP.

### Data and Source Information

## Usage and Citation Metrics

We found 452 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [SPARC SAWG](#) .

Jiang Q, et al. (2026) METTL3-mediated m6A modification of FDX1 confers resistance to cuproptosis and promotes hepatocellular carcinoma progression. *Communications biology*, 9(1), 222.

Chen H, et al. (2026) N6-methyladenosine-mediated up-regulation of ARRB2 regulates intrahepatic cholangiocarcinoma malignant progression and pemigatinib resistance through MAPK and Hippo signaling pathways. *Cell death & disease*, 17(1).

Zhan X, et al. (2026) Construction of a novel risk model for esophageal squamous cell carcinoma associated with purinergic signaling pathways and chemoradiotherapy sensitivity genes. *Frontiers in medicine*, 13, 1746281.

Wang Y, et al. (2026) FTO-mediated m6A demethylation of BCL6 promotes gastric cancer progression by suppressing ferroptosis. *RNA biology*, 23(1), 1.

Liang Y, et al. (2026) The m6A reader protein YTHDF2 facilitates HTLV-1 infectious and mitotic propagation by stabilizing Tax RNA. *Journal of virology*, 100(6), e0052926.

Luan R, et al. (2026) Pan-cancer multi-omics reveals DCAF7 as an immune-modulating prognostic driver and Wnt/ $\beta$ -catenin activator in hepatocellular carcinoma. *Clinical and translational medicine*, 16(1), e70572.

Chen Q, et al. (2026) YTHDC1-Mediated m6A Modification of MAGI3 mRNA Regulates Proliferation and Differentiation of Myoblasts. *Journal of agricultural and food chemistry*, 74(1), 1804.

Zhang Z, et al. (2026) N6-methyladenosine modification of NEU1 mediated by METTL3 exacerbates angiotensin II-induced atrial fibrillation. *Cell adhesion & migration*, 20(1), 2650272.

Ding X, et al. (2026) Xinfeng capsule attenuates ankylosing spondylitis by downregulating YTHDC1-mediated m6A modification of LINC01579 and suppressing IL-17/NF- $\kappa$ B signaling. *Frontiers in immunology*, 17, 1762062.

Xiong X, et al. (2026) Methyltransferase-Like 14 Promotes the Angiogenesis of Hepatocellular Carcinoma via Targeting Vascular Endothelial Growth Factor A. *Cancer reports (Hoboken, N.J.)*, 9(6), e70592.

Tang YZ, et al. (2026) Circ\_0006174 Drives Triple Negative Breast Cancer Progression and Immune Escape Through Regulating miR-3139/PD-L1 Axis. *The Kaohsiung journal of medical sciences*, 42(6), e70156.

Wang Y, et al. (2026) METTL3 inhibits LINC00312 to suppress osteoporosis progression in a YTHDF2-dependent manner. *International journal of molecular medicine*, 57(1).

Jiang R, et al. (2026) Methyltransferase like 3 promotes thyroid folliculogenesis via coordinating cell differentiation and polarization. *Journal of translational internal medicine*, 14(1), 96.

Liu Y, et al. (2026) ALKBH5 promotes ovarian cancer progression by activating Notch2 signaling. *Biological procedures online*, 28(1).

Du T, et al. (2026) ALKBH5 facilitates Srgn stability via m6A demethylation to disrupt blood-testis barrier integrity in the high-fat diet mice. *Cellular and molecular life sciences : CMLS*, 83(1).

Zhang D, et al. (2026) Dynamic m<sup>6</sup>A methylation during bovine preadipocyte differentiation and functional implication of the m<sup>6</sup>A writer METTL14. *BMC genomics*, 27(1).

Qiu K, et al. (2026) RBM15/IGF2BP2-PTPRH m6A regulatory axis in non-small cell lung cancer. *Cellular oncology (Dordrecht, Netherlands)*, 49(3).

Cheng J, et al. (2026) ADAMDEC1-driven CCL2-CCR2-PD-1 axis in esophageal squamous cell carcinoma: a dual threat of O-GlcNAcylation and m6A methylation in neoadjuvant therapy resistance and immune evasion. *Cellular oncology (Dordrecht, Netherlands)*, 49(2).

Ren H, et al. (2026) The PRKN/METTL3/CLDN2 axis promotes colorectal cancer development through epigenetic mechanisms. *Cell biology and toxicology*, 42(1).

Li L, et al. (2026) Diabetic Kidney Disease Progression Alleviated in Mice by ALKBH5-Mediated UC-MSCs-Derived Exosomes That Inhibit TRAF6 m6A Modification and Promote M2 Macrophage Polarisation. *Endocrinology, diabetes & metabolism*, 9(1), e70131.